Ticker Details
Neurocrine Biosciences, Inc. Neurocrine Biosciences Inc engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.
IPO Date:	May 23, 1996
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$15.76B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.87 | 1.95%
Avg Daily Range (30 D):	$1.89 | 1.36%
Avg Daily Range (90 D):	$1.68 | 1.25%

Institutional Daily Volume
Avg Daily Volume:	.69M
Avg Daily Volume (30 D):	1.01M
Avg Daily Volume (90 D):	.92M

Trade Size
Avg Trade Size (Sh.):	90
Avg Trade Size (Sh.) (30 D):	46
Avg Trade Size (Sh.) (90 D):	45

Institutional Trades
Total Institutional Trades:	12,341
Avg Institutional Trade:	$4.05M
Avg Institutional Trade (30 D):	$8.86M
Avg Institutional Trade (90 D):	$10.06M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$9.64M
Avg Closing Trade (30 D):	$26.23M
Avg Closing Trade (90 D):	$26.15M
Avg Closing Volume:	100.97K

News

May 1, 2026 @ 6:36 AM Nxera Pharma Operational Highlights and Consolidat... Source: Nxera Pharma

Apr 12, 2026 @ 11:30 PM Nxera Pharma’s Partner Neurocrine Bioscienc... Source: Na

Apr 6, 2026 @ 8:20 PM Why Soleno Therapeutics Stock Rocketed Higher on M... Source: Eric Volkman

Apr 6, 2026 @ 12:13 PM Neurocrine Buys Soleno To Tap High-Growth Rare Dis... Source: Vandana Singh

Mar 23, 2026 @ 5:17 PM Biohaven Stock Down 70% but One Fund's New $6 Mill... Source: Jonathan Ponciano

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$6.71	$1.97	$1.54
Diluted EPS	$6.49	$1.91	$1.48
Revenue	$3.1B	$814.5M	$805.5M
Gross Profit	$3.05B	$800.7M	$787.9M
Net Income / Loss	$668.6M	$197.9M	$153.7M
Operating Income / Loss	$788.9M	$193.4M	$210.9M
Cost of Revenue	$56.7M	$13.8M	$17.6M
Net Cash Flow	$72.4M	$-446.5M	$372.8M
PE Ratio